Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
多中心院内生产的抗CD19 CAR-T细胞可使B细胞恶性肿瘤患者获得较高的缓解率。
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-021-27312-6
Maschan, Michael; Caimi, Paolo F; Reese-Koc, Jane; Sanchez, Gabriela Pacheco; Sharma, Ashish A; Molostova, Olga; Shelikhova, Larisa; Pershin, Dmitriy; Stepanov, Alexey; Muzalevskii, Yakov; Suzart, Vinicius G; Otegbeye, Folashade; Wald, David; Xiong, Ying; Wu, Darong; Knight, Adam; Oparaocha, Ibe; Ferencz, Beatrix; Roy, Andre; Worden, Andrew; Kruger, Winfried; Kadan, Michael; Schneider, Dina; Orentas, Rimas; Sekaly, Rafick-Pierre; de Lima, Marcos; Dropulić, Boro
T细胞
T细胞
免疫/内分泌
肿瘤
B细胞
CD19
细胞生物学
肿瘤免疫